Sumatriptan, a serotonin 5HT 1B receptor agonist, acutely reduces insulin secretion and sensitivity and glucose effectiveness in overweight humans: A double‐blinded placebo‐controlled cross‐over trial
Diabetes, Obesity and Metabolism · 2023
DOI: 10.1111/dom.15176 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Rajna Golubic und 5 weiteren Autor:innen. Beteiligte Einrichtung: Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK. Hauptthemen laut MEDLINE: Glucose, Insulin Resistance. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Diabetes Research and Wellness Foundation.
Abstract (Originalsprache)
Aim
Evidence from mouse models suggests that brain serotonergic pathways control blood glucose. We hypothesized that sumatriptan (5HT 1B ‐receptor agonist) would alter glucose homeostasis in humans. Materials and Methods We conducted a two‐visit random‐order double‐blinded placebo‐controlled cross‐over trial in 10 overweight adults that were otherwise healthy. Participants received sumatriptan (single dose, 100 mg) or placebo before undergoing a 60‐min intravenous glucose tolerance test, followed by a 120‐min hyperinsulinaemic euglycaemic clamp.
Results
Glucose excursion was greater during intravenous glucose tolerance test with sumatriptan compared with placebo [iAUC 0‐60 min 316 (268‐333) vs. 251 (197‐319) min/mmol/L p = .047]. This was probably explained by a combination of reduced circulating insulin levels [iAUC 0‐10 min 1626 (1103‐2733) vs. 2336 (1702‐3269) min/pmol/L, p = .005], reduced insulin sensitivity [M/I‐value 2.11 (1.15, 4.05) vs. 3.03 (1.14, 4.90) mg/kg/min per pmol/L, p = .010] and glucose effectiveness [S G 0.17 (0.12, 0.21) vs. 0.22 (0.18, 0.65)/min, p = .027].
Conclusions
5HT 1B receptors have a glucoregulatory role in humans, probably acting on insulin secretion, insulin sensitivity and glucose effectiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
- Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK.
- Department of Cell Biology, Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts, USA.
- Pediatric Endocrinology, Yale University School of Medicine, New Haven, Connecticut, USA.
ORCID-Profile: Rajna Golubic, Mark L Evans
Förderung
- Diabetes Research and Wellness Foundation
Zitieren
APA
Golubic, R., Hussein Ismail, M., Josipovic, M., Kennet, J., Galderisi, A., & Evans, M. L. (2023). Sumatriptan, a serotonin 5HT 1B receptor agonist, acutely reduces insulin secretion and sensitivity and glucose effectiveness in overweight humans: A double‐blinded placebo‐controlled cross‐over trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15176
Vancouver
Golubic R, Hussein Ismail M, Josipovic M, Kennet J, Galderisi A, Evans ML. Sumatriptan, a serotonin 5HT 1B receptor agonist, acutely reduces insulin secretion and sensitivity and glucose effectiveness in overweight humans: A double‐blinded placebo‐controlled cross‐over trial. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15176
BibTeX
@article{Golubic2023,
author = {Golubic, Rajna and Hussein Ismail, Mouhamad and Josipovic, Masa and Kennet, Jane and Galderisi, Alfonso and Evans, Mark L},
title = {Sumatriptan, a serotonin 5HT 1B receptor agonist, acutely reduces insulin secretion and sensitivity and glucose effectiveness in overweight humans: A double‐blinded placebo‐controlled cross‐over trial},
journal = {Diabetes, Obesity and Metabolism},
year = {2023},
doi = {10.1111/dom.15176}
}
EUVIMED